Topics

Cambrooke Therapeutics, Inc. Company Profile

04:21 EDT 17th September 2019 | BioPortfolio

Founded in 2000, Cambrooke is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious chronic unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are today focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com.


News Articles [906 Associated News Articles listed on BioPortfolio]

Cambrooke Therapeutics, Inc. Becomes Ajinomoto Cambrooke, Inc.

Cambrooke Therapeutics, Inc. announced it has changed its corporate name to Ajinomoto Cambrooke, Inc. effective April 1, 2019. In November 2017, Cambrooke became part of ...

Cambrooke Therapeutics and Trovita Health Science Announce Strategic Alliance for ENU® Nutrition

Cambrooke Therapeutics, a member of The Ajinomoto Group, and Trovita Health Science, a specialty medical nutrition company, announce a joint marketing

Sarepta Therapeutics Acquires Myonexus Therapeutics For $165 Million

WASHINGTON (dpa-AFX) - Sarepta Therapeutics Inc. (SRPT), Wednesday said it has exercised its option to acquire Myonexus Therapeutics, a clinical-stage biotechnology company developing transformati...

Clover Therapeutics Launches With Eye on Age-Related Ocular Diseases

Clover Therapeutics, which sprung out of Clover Health, is supported by a number of biotech and pharma veterans, including Pfizer veteran Cheng Zhang, who is heading up therapeutics, and Genentech vet...

e-Therapeutics - The benefits of partnerships and cost control

Edison Investment Research - Pharmaceuticals & healthcare - e-Therapeutics: e-Therapeutics' (ETX) FY19 results demonstrated continued financial prudence and its focus on partnering, out-licensing a...

IRW-News: XPhyto Therapeutics Corp.: XPhyto Therapeutics startet Notierung an Frankfurter Börse

IRW-PRESS: XPhyto Therapeutics Corp.: XPhyto Therapeutics startet Notierung an Frankfurter Börse Vancouver (Kanada), 13. August 2019. XPhyto Therapeutics Corp. (CSE: XPHY) (XPhyto oder das Unterne...

Vertex Expands Collaboration with CRISPR Therapeutics and Acquires Exonics Therapeutics

BOSTON & WATERTOWN, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company is enhancing its gene editing capab...

Nohla’s Christianson Joins Rainier Therapeutics as Chief Technical Officer

Gary Christianson has been appointed chief technical officer of San Leandro, CA-based Rainier Therapeutics. Christianson was most recently chief operating officer at Nohla Therapeutics in Seattle. His...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]

NA

Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]

NA

Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [431 Associated PubMed Articles listed on BioPortfolio]

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls.

Antiglaucoma EP Agonists: A Long Road That Led Somewhere.

For >2 decades, EP agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first...

Glycan analysis for protein therapeutics.

Glycosylation can be a critical quality attribute for protein therapeutics due to its extensive impact on product safety and efficacy. Glycan characterization is important in the process of protein dr...

Clinical Trials [185 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1367 Associated Companies listed on BioPortfolio]

Cambrooke Therapeutics Inc.

Founded in 2000, Cambrooke Therapeutics, a proud member of The Ajinomoto Group, is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition pro...

Cambrooke Therapeutics, Inc. and Ajinomoto Co. Inc.

Founded in 2000, Cambrooke is a Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious, chronic, unmet medic...

Cambrooke Therapeutics, Inc.

Founded in 2000, Cambrooke is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with seriou...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Cambrooke Therapeutics, Inc." on BioPortfolio

We have published hundreds of Cambrooke Therapeutics, Inc. news stories on BioPortfolio along with dozens of Cambrooke Therapeutics, Inc. Clinical Trials and PubMed Articles about Cambrooke Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cambrooke Therapeutics, Inc. Companies in our database. You can also find out about relevant Cambrooke Therapeutics, Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Epilepsy
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset.  (Oxford Medical Dictionary).  A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...


Corporate Database Quicklinks



Searches Linking to this Company Record